pyridinolcarbamate has been researched along with Lung Adenocarcinoma in 1 studies
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, Z | 1 |
| Peng, Y | 1 |
| Gao, J | 1 |
| Zhou, M | 1 |
| Shi, L | 1 |
| Zhao, F | 1 |
| Wang, C | 1 |
| Tian, X | 1 |
| Feng, L | 1 |
| Huo, X | 1 |
| Zhang, B | 1 |
| Liu, M | 1 |
| Fang, D | 1 |
| Ma, X | 1 |
1 other study available for pyridinolcarbamate and Lung Adenocarcinoma
| Article | Year |
|---|---|
The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis.
Topics: Adenocarcinoma of Lung; Carcinogenesis; Cell Transformation, Neoplastic; Cyclooxygenase 2; HSP90 Hea | 2023 |